Mometasone furoate nasal spray: A review of safety and systemic effects

Drug Safety

Volumn 30, Issue 4, 2007, Pages 317-326

  Zitt, Myron ^a,c   Kosoglou, Teddy ^b   Hubbell, James ^b  

^a STATE UNIVERSITY OF NEW YORK   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c Queens Long Island Medical Group   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE DIPROPIONATE; BECLOMETHASONE 17 MONOPROPIONATE; BUDESONIDE; CORTICOSTEROID; DRUG METABOLITE; FLUNISOLIDE; FLUTICASONE PROPIONATE; MOMETASONE FUROATE; PLACEBO; PREDNISONE; TRIAMCINOLONE ACETONIDE; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ALLERGIC RHINITIS; ATROPHY; BODY HEIGHT; BONE DENSITY; CATARACT; CLINICAL TRIAL; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EXPOSURE; DRUG FORMULATION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY NOSE; EPISTAXIS; GLAUCOMA; GROWTH DISORDER; GROWTH INHIBITION; GROWTH RATE; HEADACHE; HUMAN; HYPOTHALAMUS HYPOPHYSIS SYSTEM; INTRAOCULAR PRESSURE; MYOPATHY; NOSE IRRITATION; NOSE POLYP; NOSE SEPTUM PERFORATION; OSTEOPOROSIS; PHARYNGITIS; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; SIDE EFFECT; SKIN BRUISING; SORE THROAT; THROAT IRRITATION; UPPER RESPIRATORY TRACT INFECTION; VIRUS INFECTION;

EID: 34247207122     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200730040-00004     Document Type: Review

References (51)

1. American Academy of Allergy, Asthma and Immunology. The allergy report: II. Diseases of the atopic diathesis [online]. Available from URL: http://www.aaaai.org/ar/volume2.pdf [Accessed 2006 Jun 16]
2. Bousquet J, van Cauwenberge P, Khaltaev N, et al. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001; 108 Suppl. 5: S147-334
3. Naclerio RM. Allergic rhinitis. N Engl J Med 1991; 325 (12): 860-9
4. Stanbury RM, Graham EM. Systemic corticosteroid therapy: side effects and their management. Br J Ophthalmol 1998; 82 (6): 704-8
5. Tattersfield AE, Harrison TW, Hubbard RB, et al. Safety of inhaled corticosteroids. Proc Am Thorac Soc 2004; 1 (3): 171-5
6. Lipworth BJ, Jackson CM. Safety of inhaled and intranasal corticosteroids: lessons for the new millennium. Drug Saf 2000; 23 (1): 11-33
7. Allen DB. Systemic effects of intranasal steroids: an endocrinologist's perspective. J Allergy Clin Immunol 2000; 106 Suppl. 4: S179-90
8. Esmailpour N, Ḧogger P, Rohdewald P. Binding of glucocorticoids to human nasal tissue in vitro. Int Arch Allergy Immunol 2000; 122 (2): 151-4
9. Cave A, Arlett P, Lee E. Inhaled and nasal corticosteroids: factors affecting the risks of systemic adverse events. Pharmacol Ther 1999; 83 (3): 153-79
10. Derendorf H, Hochhaus G, Meibohm B, et al. Pharmacokinetics and pharmacodynamics of inhaled corticosteroids. J Allergy Clin Immunol 1998; 101 (4): S440-6
11. Davies RJ, Nelson HS. Once-daily mometasone furoate nasal spray: efficacy and safety of a new intranasal glucocorticoid for allergic rhinitis. Clin Ther 1997; 19 (1): 27-38
12. Smith CL, Kreutner W. In vitro glucocorticoid receptor binding and transcriptional activation by topically active glucocorticoids. Arzneimittelforschung 1998; 48 (9): 956-60
13. Berkowitz RB, Roberson S, Zora J, et al. Mometasone furoate nasal spray is rapidly effective in the treatment of seasonal allergic rhinitis in an outdoor (park), acute exposure setting. Allergy Asthma Proc 1999; 20 (3): 167-72
14. Bronsky EA, Aaronson DW, Berkowitz RB, et al. Dose ranging study of mometasone furoate (Nasonex) in seasonal allergic rhinitis. Ann Allergy Asthma Immunol 1997; 79 (1): 51-6
15. Graft D, Aaronson D, Chervinsky P, et al. A placebo- and active-controlled randomized trial of prophylactic treatment of seasonal allergic rhinitis with mometasone furoate aqueous nasal spray. J Allergy Clin Immunol 1996; 98 (4): 724-31
16. Hebert JR, Nolop K, Lutsky BN. Once-daily mometasone furoate aqueous nasal spray (Nasonex) in seasonal allergic rhinitis: an active- and placebo-controlled study. Allergy 1996; 51 (8): 569-76
17. Meltzer EO, Berger WE, Berkowitz RB, et al. A dose-ranging study of mometasone furoate aqueous nasal spray in children with seasonal allergic rhinitis. J Allergy Clin Immunol 1999; 104 (1): 107-14
18. Drouin M, Yang WH, Bertrand B, et al. Once daily mometasone furoate aqueous nasal spray is as effective as twice daily beclomethasone dipropionate for treating perennial allergic rhinitis patients. Ann Allergy Asthma Immunol 1996; 77 (2): 153-60
19. Mandl M, Nolop K, Lutsky BN, et al. Comparison of once daily mometasone furoate (Nasonex) and fluticasone propionate aqueous nasal sprays for the treatment of perennial rhinitis. Ann Allergy Asthma Immunol 1997; 79 (4): 370-8
20. Bende M, Carrillo T, V́ona I, et al. A randomized comparison of the effects of budesonide and mometasone furoate aqueous nasal sprays on nasal peak flow rate and symptoms in perennial allergic rhinitis. Ann Allergy Asthma Immunol 2002; 88 (6): 617-23
21. Small CB, Hernandez J, Reyes A, et al. Efficacy and safety of mometasone furoate nasal spray in nasal polyposis. J Allergy Clin Immunol 2005; 116 (6): 1275-81
22. Stj̈arne P, Mosges R, Jorissen M, et al. A randomized controlled trial of mometasone furoate nasal spray for the treatment of nasal polyposis. Arch Otolaryngol Head Neck Surg 2006; 132 (2): 179-85
23. Meltzer EO, Charous BL, Busse WW, et al. Added relief in the treatment of acute recurrent sinusitis with adjunctive mometasone furoate nasal spray. J Allergy Clin Immunol 2000; 106 (4): 630-7
24. Nayak AS, Settipane GA, Pedinoff A, et al. Effective dose range of mometasone furoate nasal spray in the treatment of acute rhinosinusitis. Ann Allergy Asthma Immunol 2002; 89 (3): 271-8
25. Brannan MD, Herron JM, Affrime MB. Safety and tolerability of once-daily mometasone furoate aqueous nasal spray in children. Clin Ther 1997; 19 (6): 1330-9
26. Daley-Yates PT, Kunka RL, Yin Y, et al. Bioavailability of fluticasone propionate and mometasone furoate aqueous nasal sprays. Eur J Clin Pharmacol 2004; 60 (4): 265-8
27. Schenkel E. Features of mometasone furoate nasal spray and its utility in the management of allergic rhinitis. Expert Opin Pharmacother 2003; 4 (9): 1579-91
28. Teng XW, Cutler DJ, Davies NM. Mometasone furoate degradation and metabolism in human biological fluids and tissues. Biopharm Drug Dispos 2003; 24 (8): 321-33
29. Skoner DP, Gentile D, Angelini B, et al. The effects of intranasal triamcinolone acetonide and intranasal fluticasone propionate on short-term bone growth and HPA axis in children with allergic rhinitis. Ann Allergy Asthma Immunol 2003; 90 (1): 56-62
30. Lipworth BJ, Seckl JR. Measures for detecting systemic bioactivity with inhaled and intranasal corticosteroids. Thorax 1997; 52 (5): 476-82
31. Brannan MD, Herron JM, Reidenberg P. Lack of HPA axis suppression following 36 days of intranasal mometasone furoate [abstract no. P207]. American College of Allergy, Asthma and Immunology Annual Meeting; 1997 Nov 7-12; San Diego (CA). Ann Allergy Asthma Immunol 1997; 78: 154
32. Brannan MD, Seiberling M, Cutler DL, et al. Lack of systemic activity with intranasal mometasone furoate [abstract]. J Allergy Clin Immunol 1996; 97 Suppl.: S198
33. Wilson AM, Sims EJ, McFarlane LC, et al. Effects of intranasal corticosteroids on adrenal, bone, and blood markers of systemic activity in allergic rhinitis. J Allergy Clin Immunol 1998; 102 (4): 598-604
34. Lee DKC, Robb FM, Sims EJ, et al. Systemic bioactivity of intranasal triamcinolone and mometasone in perennial allergic rhinitis. Br J Clin Pharmacol 2003; 55 (3): 310-3
35. Galant SP, Melamed IR, Nayak AS, et al. Lack of effect of fluticasone propionate nasal spray on the hypothalamic-pituitary-adrenal axis in 2- and 3-year-old patients. Pediatrics 2003; 112 (1): 96-100
36. Cutler DL, Banfield C, Melton B, et al. Safety of mometasone furoate nasal spray in children with allergic rhinitis as young as 2 years of age: a randomized controlled trial. Pediatr Asthma Allergy Immunol 2006; 19 (3): 146-53
37. Schenkel EJ, Skoner DP, Bronsky EA, et al. Absence of growth retardation in children with perennial allergic rhinitis after one year of treatment with mometasone furoate aqueous nasal spray. Pediatrics 2000; 105 (2): E22
38. Dibildox J. Safety and efficacy of mometasone furoate aqueous nasal spray in children with allergic rhinitis: results of recent clinical trials. J Allergy Clin Immunol 2001; 108 Suppl. 1: S54-8
39. Gawchik S, Goldstein S, Prenner B, et al. Relief of cough and nasal symptoms associated with allergic rhinitis by mometasone furoate nasal spray. Ann Allergy Asthma Immunol 2003; 90 (4): 416-21
40. Lundblad L, Sipil̈a P, Farstad T, et al. Mometasone furoate nasal spray in the treatment of perennial non-allergic rhinitis: a Nordic, multicenter, randomized, double-blind, placebo-controlled study. Acta Otolaryngol 2001; 121 (4): 505-9
41. Meltzer EO, Jalowayski AA, Orgel HA, et al. Subjective and objective assessments in patients with seasonal allergic rhinitis: effects of therapy with mometasone furoate nasal spray. J Allergy Clin Immunol 1998; 102 (1): 39-49
42. Salib RJ, Howarth PH. Safety and tolerability profiles of intranasal antihistamines and intranasal corticosteroids in the treatment of allergic rhinitis. Drug Saf 2003; 26 (12): 863-93
43. Benninger MS, Hadley JA, Osguthorpe JD, et al. Techniques of intranasal steroid use. Otolaryngol Head Neck Surg 2004; 130 (1): 5-24
44. Marple B, Roland P, Benninger M. Safety review of benzalkonium chloride used as a preservative in intranasal solutions: an overview of conflicting data and opinions. Otolaryngol Head Neck Surg 2004; 130 (1): 131-41
45. Kerscher MJ, Hart H, Korting HC, et al. In vivo assessment of the atrophogenic potency of mometasone furoate, a newly developed chlorinated potent topical glucocorticoid as compared to other topical glucocorticoids old and new. Int J Clin Pharmacol Ther 1995; 33 (4): 187-9
46. Minshall E, Ghaffar O, Cameron L, et al. Assessment by nasal biopsy of long-term use of mometasone furoate aqueous nasal spray (Nasonex) in the treatment of perennial rhinitis. Otolaryngol Head Neck Surg 1998; 118 (5): 648-54
47. Bross-Soriano D, Hanenberg-Milver C, Schimelmitz-Idi J, et al. Effects of three nasal topical steroids in the intraocular pressure compartment. Otolaryngol Head Neck Surg 2004; 130 (2): 187-91
48. Derby L, Maier WC. Risk of cataract among users of intranasal corticosteroids. J Allergy Clin Immunol 2000; 105 (5): 912-6
49. Howland WC III. Fluticasone propionate: topical or system effects? Clin Exp Allergy 2004; 26 Suppl. 3: 18-22
50. Opatowsky I, Feldman RM, Gross R, et al. Intraocular pressure elevation associated with inhalation and nasal corticosteroids. Ophthalmology 1995; 102 (2): 177-9
51. Ernst P, Baltzan M, Deschenes J, et al. Low-dose inhaled and nasal corticosteroid use and the risk of cataracts. Eur Resp J 2006; 27 (6): 1168-74